Diabesity: The Rising Challenge of Diabetes and Obesity and How Biocon is Taking the Lead
In the world of modern healthcare, there’s a new term that’s creating waves: Diabesity. Coined to capture the dual epidemic…
Tag: GLP-1
Retatrutide: The Next-Gen ‘Triple G’ Weight Loss Drug Shows Promising Results
Retatrutide is a promising experimental weight loss drug under development by Eli Lilly. Known as the “Triple G” drug, it…
What is GLORY-1?
GLORY-1 is an innovative investigational therapy in the field of metabolic health, designed as a dual receptor agonist targeting both…
China’s Breakthrough Obesity Drug Mazdutide Achieves Record Weight Loss in Global Study
A landmark Phase 3 clinical study of mazdutide, the world’s first dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, has been…
7 Warning Signs of Obesity: Don’t Ignore These Red Flags
Obesity isn’t just about weight—it’s a complex medical condition linked to serious health risks like diabetes, heart disease, and cancer. But…
Top Obesity Drug Stocks to Watch: The Companies Leading the Weight-Loss Revolution
The global obesity drug market is experiencing significant growth, with projections exceeding $150 billion annually in the coming decade. This…
Weight-Loss Jabs Could Slash Cancer Risk by 50%: A “Transformational” Breakthrough
Key Findings at a Glance The Study: How Weight-Loss Drugs Stack Up Against Surgery A landmark Israeli study (presented at the European Congress…